10.11.2005 Official Journal of the European Union L 294(7 (Acts whose publication is not obligatory) COMMISSION COMMISSION DECISION of 8 November 2005 on the purchase and storage of foot-and-mouth disease virus antigens (2005/780/EC) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, Having regard to Council Decision 90/424/EEC of 26 June 1990 on expenditure in the veterinary field (), and in particular Article 14 thereof, Having regard to Council Directive 2003/85/EC of 29 September 2003 on Community measures for the control of foot-and-mouth disease repealing Directive 85/511/EEC and Decisions  89/531/EEC and 91/665/EEC and amending Directive 92/46/EEC (3), and in particular Article 80(2) thereof, Whereas: (1) In accordance with Council Decision 91/666/EEC of 11 December 1991 establishing Community reserves of foot-and-mouth disease vaccines (*), stocks of antigens have been established for the express formulation of vaccines against foot-and-mouth disease and are kept for security reasons at distinct designated sites of the premises of the manufacturer. (20 Under Directive 2003/85/EC, the Commission is to ensure that Community reserves of concentrated inac- tivated antigens for the production of foot-and-mouth disease vaccines are maintained on the premises of the Community antigen and vaccine bank. (") OJ L 224, 18.8.1990, p. 19. Decision as last amended by Directive 2003/99[EC of the European Parliament and of the Council (O] L 325, 12.12.2003, p. 31). (® OJ L 306, 22.11.2003, p. 1. Directive as amended by Commission Decision 2005/615(EC (O] L 213, 18.8.2005, p. 14). () OJ L 368, 31.12.1991, p. 21. Decision as last amended by Regu- lation (EC) No 807/2003 (O] L 122, 16.5.2003, p. 36). (3)  For that purpose the number of doses and the diversity of strains and subtypes of antigens of foot-and-mouth disease viruses stored in the Community antigen and vaccine bank is to be decided taking into account the needs as estimated in the context of the contingency plans and the epidemiological situation, where appro- priate after consultation with the Community Reference Laboratory. (4)  Pending the designation of a Community Reference Laboratory for foot-and-mouth disease, account is taken of the report of the FAO World Reference Laboratory for Foot-and-Mouth Disease on a list of priority antigens recommended for antigen banks, which was endorsed by the Technical Committee of the European Commission for the Control of Foot-and-Mouth Disease (EUFMD) at the Food and Agriculture Organisation (FAO) at the 36th General Session of EUFMD. (5)  The deterioration of the foot-and-mouth disease situation in certain parts of the world requires certain stocks of antigens to be supplemented urgently in accordance with the risks associated with this development for the epide- miological situation in the Community and neighbouring countries. (6)  When deciding about the procurement of additional quantities and subtypes of foot-and-mouth disease virus antigens account should be taken of existing quantities of such antigens, of the compatibility required for combi- nation in polyvalent vaccines and of the marketing authorisation held by the manufacturer of the antigens in at least one of the Member States in accordance with Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products (¥. ( OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive 2004/28/EC (O] L 136, 30.4.2004, p. 58).